Response to comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies' by Hertel, Christina et al.
*For correspondence:
kai.kisand@ut.ee (KK);
adrian.hayday@kcl.ac.uk (AH)
Competing interest: See page 7
Funding: See page 7
Received: 07 February 2019
Accepted: 13 June 2019
Published: 27 June 2019
Reviewing editor: Detlef
Weigel, Max Planck Institute for
Developmental Biology,
Germany
Copyright Hertel et al. This
article is distributed under the
terms of the Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that the
original author and source are
credited.
Response to comment on ’AIRE-deficient
patients harbor unique high-affinity
disease-ameliorating autoantibodies’
Christina Hertel1, Dmytro Fishman2, Anna Lorenc3, Annamari Ranki4, Kai Krohn4,
Pa¨rt Peterson5, Kai Kisand5*, Adrian Hayday3,6*
1ImmunoQure AG, Dusseldorf, Germany; 2Institute of Computer Science, University
of Tartu, Tartu, Estonia; 3Peter Gorer Department of Immunobiology, King’s
College London, London, United Kingdom; 4Department of Dermatology,
Allergology and Venereology, Institute of Clinical Medicine, University of Helsinki,
Helsinki, Finland; 5Institute of Biomedicine and Translational Medicine, University of
Tartu, Tartu, Estonia; 6Francis Crick Institute, London, United Kingdom
Abstract In 2016, we reported four substantial observations of APECED/APS1 patients, who are
deficient in AIRE, a major regulator of central T cell tolerance (Meyer et al., 2016). Two of those
observations have been challenged. Specifically, ‘private’ autoantibody reactivities shared by only a
few patients but collectively targeting >1000 autoantigens have been attributed to false positives
(Landegren, 2019). While acknowledging this risk, our study-design included follow-up validation,
permitting us to adopt statistical approaches to also limit false negatives. Importantly, many such
private specificities have now been validated by multiple, independent means including the
autoantibodies’ molecular cloning and expression. Second, a significant correlation of antibody-
mediated IFNa neutralization with an absence of disease in patients highly disposed to Type I
diabetes has been challenged because of a claimed failure to replicate our findings (Landegren,
2019). However, flaws in design and implementation invalidate this challenge. Thus, our results
present robust, insightful, independently validated depictions of APECED/APS1, that have
spawned productive follow-up studies.
DOI: https://doi.org/10.7554/eLife.45826.001
Introduction
In 2016, in a paper published in Cell, we made at least four substantial observations concerning
APECED/APS1 syndrome patients who are defined by deficiency in the AIRE gene, a major regulator
of central T cell tolerance: i) that such patients share autoantibodies to a small subset of proteins,
including Type I IFNs, Interleukin-(IL) 17, and IL-22, that was previously reported (Kisand et al.,
2010; Meager et al., 2006); ii) that, quite surprisingly, many such naturally-arising antibodies are
conformation-specific and of extremely high affinity, potentially explaining their powerful neutraliz-
ing capacity; iii) that most APECED/APS1 patients additionally harbor ‘private reactivates’ collec-
tively targeting very many autoantigens; and iv) that strong antibody-mediated neutralization of
IFNa correlated significantly with an absence of Type I diabetes (T1D) in patients otherwise highly
disposed to it (Meyer et al., 2016). These observations formed the basis for several substantial fol-
low-up papers in peer-reviewed journals (Rodero et al., 2017a; Fre´mond et al., 2017;
Fishman et al., 2017).
Our 2016 paper discussed the close alignment of our first substantial observation with contempo-
raneous work by Landegren and co-workers that likewise featured a protein microarray screen of
patient versus control sera (Landegren et al., 2016). Our second substantial observation could not
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be compared because Landegren and co-workers did not investigate the properties of the autoanti-
bodies that were identified. Nonetheless, Landegren and other co-workers now dispute our remain-
ing two claims (Landegren et al., 2019). While we welcome open, constructive discourse about
science, we are disappointed by this dispute because we believe it reflects simple but important dif-
ferences between our approaches that could have been easily resolved, had Landegren and co-
workers approached us directly. Those important differences are explained below. Based on biologi-
cal significance, they are considered in reverse order to their consideration in Landegren et al.
(2019) (hereafter referred to as the comment).
Results and conclusions
No association between neutralizing autoantibodies to interferons and
Type 1 diabetes in APECED/APS1
The comment disputes our observed correlation of strongly neutralizing IFNa autoantibodies with
reduced incidence of T1D, claiming to have essentially repeated our experiment, but finding no dif-
ference in the IFN neutralization capacity of sera from APECED/APS1 patients with or without T1D.
In fact, the comparison that is described in the comment of IFN neutralization in two APECED/
APS1 patient cohorts defined simply as with or without diabetes did not repeat our experiment. We
did not claim that differential Type I IFN neutralization is the sole regulator of T1D incidence. Rather,
we hypothesized that the significance of differential Type I IFN neutralization might relate to the dif-
ferential disease development in patients uniformly displaying pathognomonic features of T1D.
Thus, we compared IFNa neutralization in two patient sub-cohorts: one presenting with T1D and
one not, but all of whom either harbored and/or had harbored disease-associated, anti-islet antibod-
ies, for example anti-GAD65, anti-GAD67, that are widely-utilized clinical indicators of T1D-risk. Sup-
porting our hypothesis, we observed a statistically significant correlation of low neutralization and
T1D, consistent with several other experiments in which we established the capacity of APECED/
APS1 autoantibodies to ameliorate immunopathology.
It is also unfortunate that an imperfect study design was employed in the comment. As presented
to us, the comparison of different sera in the comment was made at a single [high] concentration
(10%), which is inappropriate because it will most often saturate the assay, thereby failing to appro-
priately discriminate low versus high neutralizing activities. To illustrate this point, we re-examined
IFNa neutralization, using a dose-dependent, cell-based assay that measures IFN-stimulated release
of alkaline phosphatase (AP), as we previously described (Meyer et al., 2016), but mimicked the
comment in examining only the effects of 10-fold diluted sera. This masked any significant differen-
ces between GADA-seropositive patients with or without T1D (Figure 1A). By contrast, when sera
were serially diluted so as to imbue the assay with appropriate sensitivity (as described in the
Meyer et al., 2016), the patients’ broad dynamic range of IC50 values was revealed, with clear seg-
regation of the patients with and without T1D (Figure 1B and C). Indeed, among 13 patients without
T1D, the serum of only one (‘N’; Figure 1C) showed low IFNa neutralization, comparable to that of
all the patients with T1D.
The authors of the comment employed a phospho-STAT1 induction assay (Gupta et al., 2016).
This is an inherently less sensitive assay, but nonetheless when we adopted it in another new experi-
ment, we obtained the same pattern of results as we obtained with the AP assay. Namely, at high
concentrations, the sera of patients with and without T1D showed comparable activities, but at
lower, sub-saturation concentrations [50-fold dilutions], the cohort without T1D showed significantly
greater capacity to limit IFNa activity (Figure 1D). Thus, because their measurements were insuffi-
ciently sensitive to discriminate low neutralizers from high neutralizers, we believe that the experi-
mental design employed in the comment was not appropriate to compare IFN neutralization by the
sera of patients with and without T1D: as such, the comment provides no experimental basis on
which to dispute the fourth substantial observation of Meyer et al. (2016).
Finally, the observations of Meyer et al. (2016) are germane to an important clinical issue. Specif-
ically, the delayed onset and relatively rare incidence (~15%) of T1D in APECED/APS1 patients is
puzzling given that: insulin is a prototypic AIRE-regulated tissue-specific autoantigen; there is
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defective negative selection of b-cell antigen-specific T cells; pancreatic b-cells are notoriously vul-
nerable to autoimmune attack; and idiopathic T1D commonly occurs in children and adolescents
(Perheentupa, 2006; Anderson et al., 2002; Wolff et al., 2014; Sabater et al., 2005). In this con-
text, the observations of Meyer et al. (2016) suggest that IFN-neutralizing antibodies may delay
T1D onset in APECED/APS1 patients and may prevent it completely in those with very high neutral-
izing titres. This is consistent with longitudinal assessment, albeit limited, reported by in Supplemen-
tary Figure 7 of Meyer et al. (2016). When combined with increasing numbers of studies implicating
Type I IFN as pathogenic in patients at genetic risk to develop T1D (Ferreira et al., 2014;
Kallionpa¨a¨ et al., 2014; Foulis et al., 1987), our data compel us to disagree with the assertion
made in the comment that there is insufficient evidence to "embark on in-depth investigations of tar-
geting Type 1 IFNs for the treatment or prevention of Type 1 diabetes."
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Figure 1. The comparison of two different strategies to measure IFNa neutralizing capacity of APECED/APS1 serum samples. In panel (A), the same
reporter cell assay (HEK-Blue IFN-a/b cells from InvivoGen) has been applied as in Meyer et al. (2016) but at a single high serum concentration (ns:
not significant). (B) Representative fitted dose-response curves that were used in Meyer et al. (2016) to calculate IC50 values for each serum sample.
Individual curves are represented with dotted lines and those for grouped values in solid lines (mean ± SEM). (C) IC50 values (expressed as the dilution
of serum sufficient to neutralize 50% of IFNa2 activity [12.5 U/ml]) that were calculated from individual and grouped curves shown in panel B. APECED/
APS1 patients with Type 1 diabetes (T1D) are depicted in red and APECED/APS1 patients with GAD65 autoantibodies (GADA) but without T1D are in
blue. (D) Neutralization of IFNa2 activity (10 000 U/ml) required to induce pSTAT1 was tested with different dilutions of sera from GAD seropositive
patients with and without T1D. 2-way ANOVA was used to calculate P-values [ns – not significant, **p0.01, ***p0.001, ****p0.0001].
DOI: https://doi.org/10.7554/eLife.45826.002
The following source data is available for figure 1:
Source data 1.
DOI: https://doi.org/10.7554/eLife.45826.003
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No evidence for widespread autoantibody reactivity in APECED/APS1
patients
The comment disputes our observations that individual APECED/APS1 patients harbor small num-
bers of ‘private’ specificities shared by few other patients, but collectively comprising a very large
number of proteins.
In fact, our observations conspicuously mirror a key clinical aspect of APECED/APS1, namely that
each patient is highly individual in the type and range of symptoms; the rate and course of disease
progression; and, to some extent, the time-of-onset. Hence, it makes biological sense that individual
patients would harbor correspondingly diverse antibodies as causes and/or biomarkers of discrete
clinical courses.
Nonetheless, the comment argues that the private specificities comprise stochastic, irreproduc-
ible signals reflecting the high risk of false positives inherent in the statistical methods that we
employed to analyse our ProtoArray data.
Importantly, all statistical approaches need to reflect a study’s goals. For example, clinical trials
use one type of statistical method to minimize type one errors (false positives) that might mislead-
ingly indicate drug efficacy, while employing different statistical methods to minimize type two
errors (false negatives) that might obscure adverse event(s). The approach advocated in the com-
ment (and in Landegren et al., 2016) parallels the former, scoring signals in patients by comparison
to mean and standard deviation (SD) of controls, and then additionally adding a Fisher’s exact test
to exclude signals that did not confer statistical difference to the whole patient group. This is well-
suited to defining how APECED/APS1 patients differ as a group from healthy controls.
By contrast, Meyer et al. (2016) sought to characterize the nature of auto-reactivities in
APECED/APS1 patients, including private reactivities that might mirror individual clinical presenta-
tions. The Fisher’s exact test filter would exclude ‘private targets’ as outliers or false positives
because they are insufficiently frequent to significantly influence the distribution of reactivities across
the whole group (see below). Anticipating this, and knowing that no existing standard data-analysis
method can unequivocally discriminate private specificities from false positives, we compared the
signal to mean and SD of controls without the additional filter (Meyer et al., 2016).
Although, this is a standard, widely-used approach, we do not dispute that it can be confounded
by unwarranted assumptions about the behavior of the control cohorts, coupled with an imbalance
in the numbers of controls (21) and patients (81) that we examined (Meyer et al., 2016). Hence,
false positives can and will arise. Nonetheless, we consciously employed this approach because the
validation of real reactivities versus false positives was to be made by a spectrum of additional, inde-
pendent, serological, biochemical, and biological methods that were employed in Meyer et al.
(2016) and subsequently in Fre´mond et al. (2017). By contrast, in the comment (and in
Landegren et al., 2016) the authors went little beyond the ProtoArray, necessitating their adoption
of a more conservative statistical approach.
Examples of validation are as follows. First, several private anti-cytokine reactivities were vali-
dated by ELISA and by LIPS (Luciferase Immunoprecipitation – an unrelated assay platform using
independent sources of target proteins displayed in native conformation), and have since been vali-
dated independently (Meyer et al., 2016; Fishman et al., 2017; Sng et al., 2019). Furthermore, we
molecularly cloned and fully characterized such autoantibodies, for example anti-IL32g (Meyer et al.,
2016), anti-BAFF (unpublished data), and anti-IL20 (Meyer et al., 2016) detected in five, four, and
two patients, respectively, but in none of the sampled controls.
Second, LIPS likewise validated many non-cytokine targets, including but not limited to 24 of 31
testis- and cancer-associated antigens so far tested (Table 1), commonly with good correlation with
the ProtoArray signal intensities (Fishman et al., 2017). Those validated targets included twelve tes-
tis-specific and CT-antigens (PDILT, MAGE-B2, SPANXD, SPAG8, SPAG16, CT45A3, GAGE1,
GAGE7B, MAGE-B1, MAGE-A3, MAGE-4 and MAGE-A10) (Fishman et al., 2017). This overtly con-
trasts with the comment and with Landegren et al. (2016) in which the ProtoArray analysis identified
reactivity to only two CT-antigens (PDILT and MAGE-B2), providing experimental evidence that their
statistical methods were too conservative to detect patients’ private reactivities.
Third, Fishman et al. (2017) applied very stringent criteria to the data of Meyer et al. (2016),
including a further filtration of private reactivities into those shared by >3 patients. Still there
were ~1000 reactivities: 490 shared by only three patients; 245 shared by 4 but not five patients; 111
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shared by 5 but not six patients; 116 shared by >6 patients. These reactivities individually and collec-
tively displayed five conspicuous traits: (1) correlations with clinical phenotypes, for example perni-
cious anemia or vitiligo; (2) more reactivities in patients with more complex clinical phenotypes; (3) a
correlation of the average number of reactivities per patient with the severity of the AIRE gene
mutation; (4) reactivities assessed longitudinally over relatively short time-frames correlated more
closely than those sampled over longer time-frames (e.g. 10 years); and (5) reactivities mostly
increased with duration of disease (Fishman et al., 2017).
Fourth, the reactivities described by Meyer et al. (2016) were conspicuously enriched in gene-
products of two sub-classes: a) those expressed in lymphoid tissues and with no known connection
to AIRE function, but which comprise some of the strongest reactivities (as agreed by
Landegren et al., 2016 and the comment); b) diverse tissue-restricted antigens (TRAs), which were
strikingly enriched in those expressed by AIRE-expressing medullary thymic epithelial cells
(Fishman et al., 2017). Consistent with this, male antigens were also targeted in females
Table 1. Testis- and cancer- associated non-cytokine targets screened by LIPS.
Target LIPS result
SPAG8 pos
SPANXD pos
TEX264 pos
CT45A3 pos
GAPDHS pos
SPAG16 pos
PDILT pos
GAGE1 pos
SPATA7 pos
GAGE7 pos
CAPNS1 pos
KCNIP2 pos
POMZP3 pos
MAGEA4 pos
RPL12 pos
MKNK2 pos
S100A7A pos
MAGEA3 pos
MAGEB1 pos
MAGEB2 pos
MAGEA10 pos
LCN1 pos
FGF12 pos
HMGB1 pos
TSPY2 neg
MORN2 neg
CRYGD neg
GNG4 neg
RSU1 neg
PAGE1 neg
PAGE2 neg
DOI: https://doi.org/10.7554/eLife.45826.004
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(Fishman et al., 2017), whereas non-CT-antigen members of the MAGE family that are expressed in
all tissues were not observed as targets (Meyer et al., 2016; Fishman et al., 2017).
False positives could not meet any of these four sets of criteria, let alone all of them. In sum, the
potential for a signal to be a false positive does not establish that it is, particularly when its validity is
attested to by multiple independent means. The comment ignores another pitfall of ProtoArrays,
which is the under-estimation of reactivities to proteins that are not displayed well, as we and others
have noted (Ka¨rner et al., 2016; Schnack et al., 2008). Critically, ProtoArrays should serve as
guides for subsequent experiments, as was the case for Meyer et al. (2016) and a number of later
studies (Rodero et al., 2017b; Fre´mond et al., 2017; Fishman et al., 2017).
In this regard, we note that a co-author of the comment recently published a study (Sng et al.,
2019) describing a loss of B cell tolerance in APECED patients that was associated with a broad
spectrum of autoantigen reactivities, including several new non-cytoline specificities. This aligns with
the depiction of APECED/APS1 patients provided by Meyer et al. (2016).
Conceding, nonetheless, that we may have exaggerated some patient reactivities, we applied a
more conservative statistical approach to Meyer et al. (2016): namely we based z-scores on the
mean of the controls and SD across all patients plus controls. SD will now be increased by positive
reactivities in controls and/or patients, thereby reducing the risk of false positives. Interestingly, this
approach identified reactivities overlapping 81% with our original study: again, these comprised
broadly shared autoantigens and from ~30 to~100 private specificities that collectively composed a
substantial fraction of the proteome. Moreover, when this same statistical approach was applied to
an additional study in which we used an earlier version of the ProtoArray (v5.0) to interrogate sera
from 23 patients examined by Meyer et al. (2016) but with eight different healthy controls, the
overlap across the two independent studies (and platforms) was substantial and highly significant
(p<1e-06), far exceeding any overlap obtained from 100,000 random permutations of patients and
controls.
We conclude that our published and ongoing studies (Meyer et al., 2016; Fishman et al., 2017)
accurately depict the serological status of APECED/APS1 patients, viewed collectively and individu-
ally. While we acknowledge that the limited numbers of patients and appropriate controls make it
difficult to reach a precise estimate of the numbers of private specificities, there is no basis for dis-
puting the four central findings of Meyer et al. (2016), consistent with which those findings have
formed a basis for rigorous follow-up work by us and by others (Rodero et al., 2017a;
Fre´mond et al., 2017; Fishman et al., 2017; Sng et al., 2019; Rice et al., 2018; Llibre et al., 2018;
Dhir et al., 2018; Rodero et al., 2017b) that will inform our understanding of APECED/APS1 and of
autoimmune diseases more generally.
Materials and methods
Key resources table
Reagent type or resource Designation Source Identifiers
Cell line Human HEK293
cells - Type I IFNs
reporter cells
InvioGen cat # hkb-ifnab
Antibody Alexa Fluor 647
conjugated anti-STAT1
(pY701), mouse IgG2a
BD Biosciences cat # 562070
Recombinant
protein
recombinant
human IFNa2a
Miltenyi Biotech cat # 130-093-873
Reporter cell assay
The IC50 values of IFNa neutralization of serum samples were tested with the help of HEK-BlueTM
IFN-a/b reporter cells (InvivoGen) that express alkaline phosphatase (AP) under the inducible ISG54
promoter after ISGF binding to the IFN-stimulated response elements in the promoter. The cells
were grown in DMEM supplemented with heat inactivated 10% FBS and 30 g/ml blasticidin (Invivo-
Gen) and 100 g/ml Zeocin (InvivoGen). Cells were stimulated with IFNa2a (12.5 U/ml, Miltenyi Bio-
tech) that was preincubated for 2 hr with serial dilutions of recombinant antibodies or one fixed
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concentration (10%) of serum. QUANTI-Blue TM (InvivoGen) colorimetric enzyme assay was used to
determine AP in the cell culture supernatants after 21 hr of incubation. OD was measured at 620 nm
with Multiscan MCC/340 (Labsystems) ELISA reader and IC50 values were calculated from the dose-
response curves using GraphPad Prism eight software.
Phospho-STAT1 assay
Peripheral blood mononuclear cells (PBMC) from a healthy control were isolated with density gradi-
ent centrifugation and aliquoted by 500 000 cells to test tubes containing IFN-a2a (10 000 U/ml)
pre-incubated with serum dilutions for 2 hr. Tubes with or without IFN alone served as positive and
negative controls. After 15 min of stimulation of PBMCs at 37˚C, the cells were fixed immediately
with Cytofix buffer, permeabilized with Perm Buffer III and stained with PE-conjugated antibody to
phospho-STAT1 (Y701; all from BD Biosciences). Data were acquired with LSRFortessa (BD Bioscien-
ces) and analyzed with FCS Express (De Novo Software).
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